EDMONTON, Sept. 7 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced it has
received approval from the Spanish Agency for Medicines and Healthcare
Products (SAMHP) in Spain and from the Federal Institute for Medicines and
Medical Products in Germany to start patient enrolment for its pivotal
phase II/III clinical trial of MBP8298, a proprietary synthetic peptide for
the treatment of secondary progressive multiple sclerosis (SPMS).
